查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830963

生物植入物市場

Bio-Implants Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024 年生物植入物市場價值為 1,275.9 億美元，預計到 2031 年將達到 2,230.6 億美元，2025 年至 2031 年的複合年成長率預計為 8.3%。

分析師觀點：本報告概述了基於當前趨勢和推動生物植入物市場發展的因素的成長機會。生物植入物市場擴張的主要因素包括慢性病發生率的上升（尤其是在老年人群體中），以及可支配收入的增加。已開發國家和發展中國家醫療基礎設施的改善也有望顯著推動生物植入物市場的發展。

在全球範圍內，人們對美容植入物益處和技術進步的認知不斷提高。生物植入物市場正在全球範圍內成長，特別是由於牙科問題的日益普遍。此外，由於心血管和骨科疾病的發生率不斷上升，對骨科植入物和心律調節器的需求也在上升。在北美，由於強大的醫療保健體系、人們對美容植入物認知的提高以及主要行業參與者的存在，生物植入物的銷售量預計將成長。歐洲是全球第二大生物植入物市場，這得益於醫療保健技術的快速進步、對非侵入性生物植入物日益成長的需求以及老齡人口的不斷增加。然而，生物植入手術的高成本以及對生物植入物產品合理使用的需求對市場成長構成了挑戰。

市場概覽：推動生物植入物市場成長的因素包括老年人骨質退化發生率的上升、對微創手術的需求不斷成長以及生活方式相關疾病的激增。此外，預計醫療技術的進步將在未來幾年顯著影響生物植入物的市場前景。儘管醫療保健技術取得了顯著進步，但嚴重疾病的發生率不斷上升阻礙了生物植入物市場的發展。

策略洞察市場驅動力：生活方式障礙負擔加重推動市場成長糖尿病、心血管疾病和骨關節炎等生活方式相關疾病在全球日益普遍，導致大量患者患病和死亡。生物植入物（包括支架和骨架）正在成為治療這些疾病的傳統永久性植入物的可行替代方案。根據美國心臟協會2021年的一篇文章，美國每年約有4萬名兒童接受先天性心臟手術。英國心臟基金會發布的《2022年1月英國概況》報告稱，2021年約有760萬人患有心臟和循環系統疾病，其中近400萬男性和360萬女性受到影響。因此，心血管疾病盛行率的上升推動了對早期診斷和治療的需求，預計這將增加對介入性心臟病學手術和心血管生物植入物的需求。此外，口腔健康問題的顯著增加預計將增加對生物植入物的需求。世界衛生組織（WHO）2021年全球疾病負擔研究顯示，口腔疾病預計將影響全球近一半的人口，約35.8億人受到齲齒和其他牙齒問題的影響。

此外，生物植入物在管理和輸送針對肌肉骨骼疾病等疾病的特定藥物方面發揮著至關重要的作用。 《骨科》雜誌2021年1月的一篇文章指出，北京中年族群腰椎滑脫的盛行率為17.26%（男性15.98%，女性18.80%），60歲以上的女性尤其容易罹患此病。世界衛生組織報告稱，全球有17.1億人患有肌肉骨骼損傷和疾病，是導致殘疾的主要原因。 《柳葉刀風濕病學》發表的一項研究預測，到2050年，將有超過10億人患有關節、肌肉、骨骼、韌帶、肌腱和脊柱疾病，而2020年這一數字約為5億。老年人口的成長導致患有肌肉骨骼疾病和相關功能障礙的人數迅速增加，導致對植入手術和住院治療的需求增加，從而推動了生物植入物市場的發展。

分段分析：透過檢查以下分段來分析生物植入物市場：類型、材料和最終用戶。

按類型分類，生物植入物市場分為心血管植入物、骨科植入物、牙科植入物、眼科植入物及其他。心血管植入物領域在2023年佔據了相當大的市場佔有率，這得益於旨在創造創新心臟植入產品的研發熱潮。例如，2022年2月，醫療技術公司雅培宣佈在其AVEIR DR i2i關鍵臨床試驗中，首次為患者植入了無導線雙腔心律調節器系統，標誌著無導線心律調節器技術的重大技術進步。

生物植入物市場按材料分類，包括金屬、陶瓷和聚合物。速釋膠囊細分市場在 2023 年佔據最大市場佔有率，預計在預測期內將呈現最高的複合年成長率。金屬因其卓越的機械強度、耐腐蝕性和生物相容性而成為植入物的首選材料。鈦因其卓越的耐用性、輕質特性以及與人體組織的相容性而被廣泛用於骨科、牙科和心血管植入物。金屬也因其延展性、導電性和惰性而受到特殊植入應用的重視，例如心臟電極和神經探針。慢性病的日益普及以及材料科學和製造技術的進步，正在推動生物植入物對生物材料金屬的需求，鞏固其作為生物植入物市場領先材料類別的地位。

按最終用戶分類，市場分為醫院和診所以及門診手術中心。 2023年，醫院和診所佔據了生物植入物市場的較大佔有率，預計2023年至2031年期間的複合年成長率將更高。醫院和診所憑藉其全面的醫療項目和多學科的患者護理方法，吸引了大量患者，包括需要專門植入治療的患者。醫院經常與研究中心和醫療器材製造商合作，以獲取尖端的植入技術。它們在生物植入物市場中發揮著至關重要的作用，提供必要的植入物相關服務，並對生物植入物產品和製程產生巨大的需求。因此，預計在預測期內，醫院和診所數量的增加，加上醫療保健需求的不斷成長，將支持該細分市場的成長。

區域分析：生物植入物市場報告涵蓋北美、歐洲、亞太地區、中東和非洲以及南美和中美。 2023 年北美市場價值為 505.1 億美元，預計到 2031 年將達到 966.9 億美元，2023 年至 2031 年的複合年成長率為 8.5%。北美市場分為美國、加拿大和墨西哥，成長歸因於慢性病盛行率的上升和醫療基礎設施的改善。美國疾病管制與預防中心 (CDC) 2022 年 7 月的最新資料表明，冠狀動脈疾病是最常見的心臟病之一，影響美國約 2,010 萬名 20 歲及以上的成年人。此外，CDC資料顯示，每 40 秒就會發生一次心臟病，影響近 805,000 人。預計預測期內慢性病發生率的增加將推動對生物植入物的整體需求。

根據醫療保險和醫療補助服務中心的數據，到 2028 年，全國醫療保健支出預計將達到 6.2 兆美元，2019 年至 2028 年的年均成長率為 5.4%。由於全國醫療保健支出預計將增加 1.1 個百分點，預計到 2028 年醫療保健產業在經濟中的佔有率將上升到 19.7%，超過 2019 年至 2028 年的年均 GDP 成長率。因此，預計不斷成長的醫療保健支出將為市場參與者在預測期內開發生物植入物創造機會。

2023年，歐洲佔據生物植入物市場第二大佔有率，其成長得益於醫療保健技術的進步、非手術生物植入物需求的成長以及老齡化人口的成長。歐洲市場的成長得益於政府資金和醫療保健計劃、骨科疾病發病率的上升以及醫療保健領域研發活動的增加。此外，由於該地區心血管疾病發生率的上升，心血管手術數量的增加也推動了生物植入物市場的發展。

預計從 2023 年到 2031 年，亞太地區將成為全球生物植入物市場中複合年成長率最高的地區。該地區市場的成長得益於老齡人口的增加、可支配收入的提高、醫療保健投資的增加、市場參與者的擴張，以及交通事故導致的脊髓損傷的增加。亞太地區正在經歷顯著的成長，尤其是在中國和印度等新興市場。醫療保健基礎設施的擴建和為改善患者服務而增加的該領域投資，正在推動該地區生物植入物市場的發展。例如，日本慶應義塾大學 2019 年的出版品報道稱，日本約有 10 萬名患者因脊髓損傷而癱瘓。然而，iPS 技術的批准預計將在不久的將來幫助這些患者，從而可能為生物植入物市場創造機會。根據聯合國亞洲經濟社會委員會和太平洋社會發展部統計，2016年亞洲60歲以上人口占總人口的12.4%以上，預計2050年將達到13億人。

生物植入物市場報告範圍關鍵參與者分析：生物植入物市場報告中介紹的關鍵參與者包括 LifeNet Health、Smith & Nephew、Arthrex, Inc.、Clinic Lemanic、Alpha Bio Tec、MiMedx Group、Medtronic、St Jude Medical (Abbott)、Stryker Corporation、DePuy Synthes、Biomet, Inc.、Exacm、Exac)、Exacronxs Syn

最新動態：市場上的公司正在進行併購。以下是根據公司新聞稿得出的一些最新關鍵動態：

2023 年 2 月，專注於修復彎曲骨骼骨折的醫療器材開發商 CurvaFix, Inc. 推出了直徑較小的 7.5 毫米 CurvaFix IM 植入物，旨在簡化手術程序並在小骨骼中提供牢固、穩定的固定。 2022 年 6 月，ZimVie 在美國推出了經 FDA 批准的 T3 專業工程植入物和 Encode Emergence 癒合基台。 2021 年 6 月，Intelligent Implants Ltd. 的 SmartFuse 獲得美國 FDA 的突破性認證，這是一項骨科植入物技術，旨在遠端刺激、控制和監測骨骼生長，以便即時進行臨床決策，適用於首次使用腰椎融合術的患者。 2021 年 2 月，美敦力推出了 TYRX 可吸收抗菌鞘，這是一款可吸收的一次性抗菌鞘，旨在穩定心臟植入式電子設備或植入式神經刺激器。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：生物植入物市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：生物植入物市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：生物植入物市場－全球市場分析

  • 生物植入物 - 全球市場概覽
  • 生物植入物－全球市場及2031年預測

第7章：生物植入物市場-收入分析-按類型，2021-2031

  • 概述
  • 心血管植入物
  • 脊椎植入物
  • 骨科植入物
  • 牙種植體
  • 眼科植入物
  • 其他

第 8 章：生物植入物市場 - 收入分析 - 依材料，2021-2031 年

  • 概述
  • 金屬
  • 陶瓷
  • 聚合物

第9章：生物植入物市場-收入分析-按最終用戶，2021-2031

  • 概述
  • 醫院和診所
  • 門診手術中心

第 10 章：生物植入物市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 13 章：生物植入物市場 - 主要公司簡介

  • LifeNet Health
  • Smith & Nephew
  • Arthrex, Inc.
  • Clinic Lemanic
  • Alpha Bio Tec
  • MiMedx Group
  • Medtronic
  • St Jude Medical (Abbott)
  • Stryker Cooperation
  • DePuy Synthes
  • Biomet (Zimmer)
  • Exactech, Inc.
  • Cochlear Ltd
  • Straumann AG

第 14 章：附錄

簡介目錄
Product Code: TIPHE100001101

The bio-implants market was valued at US$ 127.59 billion in 2024 and is anticipated to reach US$ 223.06 billion by 2031, with an estimated CAGR of 8.3% from 2025 to 2031.

Analyst Perspective:This report outlines growth opportunities based on current trends and factors driving the bio-implants market. Key contributors to the expanding bio-implants market include the rising incidence of chronic diseases, especially among the elderly, and increasing disposable incomes. The enhancement of healthcare infrastructure in both developed and developing nations is also expected to significantly boost the bio-implants market.

Global awareness regarding the benefits of cosmetic implants and advancements in technology has risen. The bio-implants market is experiencing growth worldwide, particularly due to the increasing prevalence of dental issues. Additionally, the demand for orthopedic implants and pacemakers is on the rise due to the growing incidence of cardiovascular and orthopedic conditions. In North America, sales of bio-implants are projected to increase, driven by a strong healthcare system, heightened awareness of cosmetic implants, and the presence of major industry players. Europe ranks as the second-largest bio-implants market globally, fueled by rapid technological progress in healthcare, a growing demand for non-invasive bio-implants, and an increasing elderly population. However, the high costs associated with bio-implant procedures and the need for proper utilization of bio-implant products pose challenges to market growth.

Market Overview:Factors driving the growth of the bio-implants market include the rising incidence of bone degeneration in older adults, an increasing demand for minimally invasive surgical options, and a surge in lifestyle-related disorders. Furthermore, advancements in healthcare technology are expected to significantly influence the bio-implants market outlook in the coming years. Despite notable technological progress in healthcare, the rising prevalence of serious medical conditions has impeded the bio-implants market.

Strategic Insights Market Driver: Increasing Burden of Lifestyle Disorders Propel Market Growth

Lifestyle-related disorders such as diabetes, cardiovascular diseases, and osteoarthritis are becoming more common globally, leading to significant morbidity and mortality. Bio-implants, including stents and scaffolds, are emerging as viable alternatives to traditional permanent implants for treating these conditions. According to a 2021 article from the American Heart Association, approximately 40,000 children in the US undergo congenital heart surgery annually. The "UK Factsheet January 2022" from the British Heart Foundation reported that around 7.6 million individuals live with heart and circulatory diseases, with nearly 4 million men and 3.6 million women affected in 2021. Consequently, the rising prevalence of cardiovascular diseases is driving the demand for early diagnosis and treatment, which is expected to boost the need for interventional cardiology procedures and cardiovascular bio-implants. Additionally, a significant increase in oral health issues is anticipated to elevate the demand for bio-implants. The World Health Organization (WHO) 2021 Global Burden of Disease Study indicated that oral diseases are projected to impact nearly half of the global population, with approximately 3.58 billion individuals affected by dental caries and other dental issues.

Moreover, bio-implants play a crucial role in managing and delivering specific medications for conditions like musculoskeletal disorders. A January 2021 article in Orthopedic Surgery noted that the prevalence of lumbar spondylolisthesis among middle-aged individuals in Beijing was 17.26% (15.98% in men and 18.80% in women), with women over 60 being particularly susceptible. The WHO reports that musculoskeletal injuries and diseases affect 1.71 billion people globally, making them a leading cause of disability. Projections suggest that by 2050, over 1 billion individuals will suffer from joint, muscle, bone, ligament, tendon, and spine diseases, up from about half a billion in 2020, according to a study published in The Lancet Rheumatology. The growing elderly population is rapidly increasing the number of individuals with musculoskeletal conditions and related functional limitations, leading to a higher demand for implant procedures and hospitalizations, thus propelling the bio-implants market.

Segmental Analysis:The analysis of the bio-implants market has been conducted by examining the following segments: type, material, and end user.

By type, the bio-implants market is categorized into cardiovascular implants, orthopedic implants, dental implants, ophthalmic implants, and others. The cardiovascular implants segment accounted for a significant market share in 2023, driven by a surge in research and development aimed at creating innovative cardiac implant products. For instance, in February 2022, Abbott, a medical technology firm, announced the first patient implantation of a leadless dual-chamber pacemaker system as part of its AVEIR DR i2i pivotal clinical trial, marking a significant technological advancement in leadless pacemaker technology.

The bio-implants market, categorized by material, includes metals, ceramics, and polymers. The immediate-release capsules segment held the largest market share in 2023 and is expected to exhibit the highest CAGR during the forecast period. Metals are preferred for implant applications due to their exceptional mechanical strength, corrosion resistance, and biocompatibility. Titanium is a widely used material for orthopedic, dental, and cardiovascular implants due to its remarkable durability, lightweight nature, and compatibility with human tissue. Metals are also valued for specialized implant applications such as cardiac electrodes and neurological probes due to their malleability, electrical conductivity, and inertness. The increasing prevalence of chronic diseases and advancements in materials science and manufacturing techniques are driving the demand for biomaterial metals in bio-implants, solidifying their position as the leading material category in the bio-implants market.

By end user, the market is divided into hospitals & clinics and ambulatory surgical centers. The hospitals & clinics segment held a larger share of the bio-implants market in 2023 and is projected to register a higher CAGR from 2023 to 2031. Hospitals & clinics attract a large patient base, including those requiring specialized implant treatments, due to their comprehensive medical programs and multidisciplinary approach to patient care. Hospitals often collaborate with research centers and medical device manufacturers to access cutting-edge implant technologies. They play a crucial role in the bio-implants market by providing essential implant-related services and generating significant demand for bio-implant products and processes. Thus, the increasing number of hospitals & clinics, coupled with the rising demand for medical care, is expected to support the growth of this segment during the forecast period.

Regional Analysis:The bio-implants market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North American market was valued at US$ 50.51 billion in 2023 and is projected to reach US$ 96.69 billion by 2031, with an expected CAGR of 8.5% from 2023 to 2031. The market in North America is segmented into the US, Canada, and Mexico, with growth attributed to the rising prevalence of chronic diseases and improved healthcare infrastructure. Updated data from the Centers for Disease Control and Prevention (CDC) in July 2022 indicates that coronary artery disease is one of the most prevalent heart diseases, affecting approximately 20.1 million adults aged 20 and older in the US. Additionally, CDC data reveals that a heart attack occurs every 40 seconds, affecting nearly 805,000 individuals. The increasing incidence of chronic diseases is expected to drive the overall demand for bio-implants during the forecast period.

According to the Centers for Medicare and Medicaid Services, national healthcare spending is projected to reach US$ 6.2 trillion by 2028, growing at an average annual rate of 5.4% from 2019 to 2028. As national healthcare spending is expected to increase by 1.1 percentage points, the healthcare sector's share of the economy is anticipated to rise to 19.7% by 2028, outpacing the average annual GDP growth from 2019 to 2028. Consequently, the rising healthcare expenditure is expected to create opportunities for market players to develop bio-implants during the forecast period.

Europe holds the second-largest share of the bio-implants market in 2023, with growth attributed to technological advancements in healthcare, increased demand for non-surgical bio-implants, and a growing elderly population. The market growth in Europe is supported by government funding and healthcare initiatives, a rising incidence of orthopedic diseases, and increased research and development activities in healthcare. Furthermore, the growing number of cardiovascular surgeries due to the rising incidence of cardiovascular diseases in the region is driving the bio-implants market.

Asia Pacific is expected to exhibit the highest CAGR in the global bio-implants market from 2023 to 2031. The market growth in this region is driven by the increasing elderly population, rising disposable incomes, growing healthcare investments, and the expansion of market players, along with a rise in spinal cord injuries due to traffic accidents. Asia Pacific is experiencing significant growth, particularly in emerging markets like China and India. The expansion of healthcare infrastructure and increased investments in this sector to enhance patient services are propelling the bio-implants market in the region. For instance, a 2019 publication from Japan's Keio University reported that approximately 100,000 patients in Japan are paralyzed due to spinal cord injuries. However, the approval of iPS technology is expected to assist these patients in the near future, potentially creating opportunities in the bio-implants market. According to the United Nations Economic and Social Commission for Asia and the Department of Social Development in the Pacific, in 2016, over 12.4% of Asia's population was over 60 years old, a figure projected to reach 1.3 billion by 2050.

Bio-implants Market Report Scope Key Player Analysis:Key players profiled in the bio-implants market report include LifeNet Health, Smith & Nephew, Arthrex, Inc., Clinic Lemanic, Alpha Bio Tec, MiMedx Group, Medtronic, St Jude Medical (Abbott), Stryker Corporation, DePuy Synthes, Biomet (Zimmer), Exactech, Inc., Cochlear Ltd, and Straumann AG.

Recent Developments:Companies in the market are engaging in mergers and acquisitions. Below are some recent key developments based on company press releases:

In February 2023, CurvaFix, Inc., a medical device developer focused on repairing fractures in curved bones, launched its smaller diameter 7.5mm CurvaFix IM implant, designed to simplify surgical procedures and provide strong, stable fixation in small bones.In June 2022, ZimVie introduced the FDA-approved T3 pro-engineered implants and Encode Emergence Healing Abutment in the US.

In June 2021, Intelligent Implants Ltd. received breakthrough designation from the US FDA for SmartFuse, an orthopedic implant technology designed to remotely stimulate, control, and monitor bone growth for real-time clinical decisions, indicated for first-use patients undergoing lumbar spinal fusion.

In February 2021, Medtronic launched the TYRX Absorbable Antibacterial Sheath, an absorbable, disposable antibacterial sheath designed for stabilizing a cardiac implantable electronic device or implanted neurostimulator.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Bio Implants Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Bio Implants Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Bio Implants Market - Global Market Analysis

  • 6.1 Bio Implants - Global Market Overview
  • 6.2 Bio Implants - Global Market and Forecast to 2031

7. Bio Implants Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 7.1 Overview
  • 7.2 Cardiovascular Implants
  • 7.3 Spinal Implants
  • 7.4 Orthopedics Implants
  • 7.5 Dental Implants
  • 7.6 Ophthalmic Implants
  • 7.7 Others

8. Bio Implants Market - Revenue Analysis (USD Million) - By Material, 2021-2031

  • 8.1 Overview
  • 8.2 Metal
  • 8.3 Ceramics
  • 8.4 Polymers

9. Bio Implants Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 9.1 Overview
  • 9.2 Hospitals and Clinics
  • 9.3 Ambulatory Surgical Centers

10. Bio Implants Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Bio Implants Market Overview
    • 10.1.2 North America Bio Implants Market Revenue and Forecasts to 2031
    • 10.1.3 North America Bio Implants Market Revenue and Forecasts and Analysis - By Type
    • 10.1.4 North America Bio Implants Market Revenue and Forecasts and Analysis - By Material
    • 10.1.5 North America Bio Implants Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Bio Implants Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Bio Implants Market
        • 10.1.6.1.1 United States Bio Implants Market, by Type
        • 10.1.6.1.2 United States Bio Implants Market, by Material
        • 10.1.6.1.3 United States Bio Implants Market, by End User
      • 10.1.6.2 Canada Bio Implants Market
        • 10.1.6.2.1 Canada Bio Implants Market, by Type
        • 10.1.6.2.2 Canada Bio Implants Market, by Material
        • 10.1.6.2.3 Canada Bio Implants Market, by End User
      • 10.1.6.3 Mexico Bio Implants Market
        • 10.1.6.3.1 Mexico Bio Implants Market, by Type
        • 10.1.6.3.2 Mexico Bio Implants Market, by Material
        • 10.1.6.3.3 Mexico Bio Implants Market, by End User
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Bio Implants Market - Key Company Profiles

  • 13.1 LifeNet Health
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Smith & Nephew
  • 13.3 Arthrex, Inc.
  • 13.4 Clinic Lemanic
  • 13.5 Alpha Bio Tec
  • 13.6 MiMedx Group
  • 13.7 Medtronic
  • 13.8 St Jude Medical (Abbott)
  • 13.9 Stryker Cooperation
  • 13.10 DePuy Synthes
  • 13.11 Biomet (Zimmer)
  • 13.12 Exactech, Inc.
  • 13.13 Cochlear Ltd
  • 13.14 Straumann AG

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud